Skip to main content
Taylor & Francis Open Select logoLink to Taylor & Francis Open Select
. 2022 Dec 15;30(6):655–662. doi: 10.1080/09286586.2022.2119258

Prevalence of Trachoma in Pre-validation Surveillance Surveys in 11 Evaluation Units (Covering 12 Districts) in Oromia Regional State, Ethiopia: Results from 2018−2020

Hirpa Miecha a,, Michael Dejene b, Dereje Adugna a, Ageru Kebede c, Damtew Yadeta a, Addisu Alemayehu d, Aemero Abateneh e, Mihiret Dayessa f, Muhammed Shafi g, Emawayish Taye c, Leta Balcha c, Nebiyu Negussu b, Belete Mengistu d, Rebecca Willis h, Cristina Jimenez i, Ana Bakhtiari h, Sarah Boyd h, Biruk Kebede b, Fantahun Tadesse b, Ayele Mamo a, Mengistu Bekele a, Zelalem Sinke a, Anthony W Solomon j, Emma M Harding-Esch k
PMCID: PMC10581667  PMID: 36519777

ABSTRACT

Purpose

Interventions to reduce the prevalence of trachoma and transmission of ocular Chlamydia trachomatis have been implemented in Oromia Region, Ethiopia. Following an impact survey in which the trachomatous inflammation—follicular (TF) prevalence in 1–9-year-olds is <5%, a surveillance survey is recommended 2 years later, without additional antibiotic treatment. We report results of surveillance surveys in 11 evaluation units (EUs) covering 12 districts in Oromia Region, to plan whether future interventions are needed.

Method

We use a two-stage cluster-sampling cross-sectional survey design. In each EU, 26 clusters (villages) were systematically selected with probability proportional to size; from each cluster, 30 households were selected using compact segment sampling. Water, sanitation and hygiene (WASH) access was assessed in all selected households. All residents of selected households aged ≥1 year were examined for TF and trachomatous trichiasis (TT) by certified graders.

Result

Of 31,991 individuals enumerated, 29,230 (91% of) individuals were examined. Eight EUs had an age-adjusted TF prevalence in 1−9-year-olds of ≥5% and seven had a TT prevalence unknown to the health system among adults aged ≥15 years of ≥0.2%. About one-third of visited households had access to an improved water source for drinking, and 5% had access to an improved latrine.

Conclusion

Despite TF reductions to <5% at impact survey, prevalence recrudesced to ≥5% in all but three of the 11 EUs. Operational research is needed to understand transmission dynamics and epidemiology, in order to optimise elimination strategies in high-transmission settings like these.

KEYWORDS: trachoma, trichiasis, epidemiology, recrudescence

Introduction

Trachoma is an eye disease caused by certain strains of the Chlamydia trachomatis bacterium. Infection is frequently first encountered in infancy or childhood and in endemic areas, recurs frequently.1,2 Transmission is thought to occur through transfer of eye and nose secretions, directly via contact with hands and faces of infected people, or indirectly via fomites (shared clothing) or the eye-seeking Musca sorbens fly.3,4 Access to water, sanitation and hygiene (WASH) is considered key to limiting transmission.5 Consequently, the World Health Organization (WHO)-recommended strategy for trachoma elimination as a public health problem, known by the acronym “SAFE”, includes facial cleanliness (F) and environmental improvement (E); the S and A components of SAFE are surgery (for trachomatous trichiasis, TT) and antibiotic mass drug administration (MDA; to clear infection), respectively.6

Trachoma is a public health problem in 44 countries, and is responsible for the blindness or visual impairment of about 1.9 million people. Based on March 2020 data, 137 million people globally live in trachoma endemic areas and are at risk of trachoma blindness.7

Africa is the continent most affected by trachoma. Ethiopia is the second most populous country in Africa and has the highest national burden of trachoma worldwide.7–9,10

Oromia Regional State is Ethiopia's most populous region.11 Oromia has more than 39 million people an area of about 363,136 km2 and is administratively divided into 21 zones and 337 woredas (districts).12

Oromia Regional Health Bureau conducted population-based trachoma prevalence surveys between December 2012 and July 2014, using Global Trachoma Mapping Project (GTMP) protocols.9 These surveys revealed that 56 evaluation units (EUs) covering 218 districts needed implementation of the A, F and E components of the SAFE strategy for 3 years before impact surveys could be undertaken. It was further noted that 72 EUs covering 240 districts had TT prevalence above the elimination threshold of 0.2% in those aged ≥15 years.9

Starting from 2013, SAFE has been implemented in Oromia. About 256 integrated eye care workers (IECWs) have been trained and deployed with the necessary equipment to undertake TT surgery. As a result, over 146,724 TT cases have been operated, compared to the previously estimated backlog of 200,000, contributing to the national TT backlog clearance initiative. In addition, more than 113 million doses of azithromycin (Zithromax, Pfizer Inc, New York, NY, USA; donated through the International Trachoma Initiative, Decatur, GA, USA)13 have been distributed in EUs requiring MDA. Much effort has been invested developing clean water sources, constructing latrines and encouraging latrine usage throughout the region by the regional government. In addition, awareness creation activities have been implemented by health extension workers, as part of the regional health sector plan, on the importance of face washing, hand hygiene and environmental sanitation activities to reducing individual risk of contracting trachoma.12

In this manuscript, we present trachoma prevalence data from surveillance surveys conducted in 11 EUs (covering 12 districts) of Oromia between 2018 and 2020. These surveys were undertaken, as recommended by WHO,14 after impact surveys demonstrated a trachomatous inflammation—follicular (TF) prevalence in 1–9-year-olds of <5%, in order to see whether reductions in TF prevalence had been sustained in the absence of ongoing MDA.

Methods

Ethics approval and consent to participate

Ethical approval was obtained from Oromia Regional State Health Bureau ethical clearance committee (protocol no. BEFO/AHDFIDh/1-69/3079). Official letters of permission were also obtained from each concerned zone and district health office. Tropical Data survey support was approved by the London School of Hygiene & Tropical Medicine Observational Ethics Committee (16105).

Before the commencement of data collection, each individual taking part in these surveys was informed about their purpose, procedures and confidentiality of the information provided. Consent was recorded in Android smartphones. Parents or guardians of children gave consent on their children’s behalf. Individuals diagnosed with active trachoma (TF and/or trachomatous inflammation—intense, TI) or any other likely-bacterial conjunctivitis were provided with two tubes of 1% tetracycline eye ointment to be used twice daily for six weeks and shown how to administer it. People identified with TT were referred to the nearest appropriate health facility for management.

Survey design, participant selection

Community-based cross-sectional surveys were conducted. For the purposes of trachoma elimination, WHO defines an EU as “the normal administrative unit for health-care management, consisting of a population unit between 100,000 and 250,000 persons”.15 In these surveys, eleven EUs covering twelve districts from five zones of Oromia were included. A two-stage cluster sampling technique was employed to select study participants. In each EU, lists of clusters (defined for these surveys as a gare, a sub-unit of a village with an average of 30 households each) were obtained from district health offices. Among these lists, 30 survey clusters were randomly selected per EU for data collection. A structured questionnaire on access to WASH facilities was administered to the head (or another adult resident) of each selected household, and all residents of the household aged ≥1 year were invited to have both eyes examined for trachoma.

Sampling and sample size

Survey sample size was estimated using the single population proportion for precision formula.16 We aimed to estimate TF prevalence of 4% in 1–9-year-olds with a precision of ±2% at the 95% confidence level. Our estimated mean number of 1–9-year-old children per household was 1.5, based on the expectation that 1–9-year-olds make up 35% of the total population.17 Assuming a design effect of 2.6318 and after factoring in a non-response inflation factor of 1.2, it was determined that 1,164 children aged 1–9 years should be enumerated per EU. Twenty-six to twenty-eight clusters comprising 30 households were needed in each EU to enumerate that number of 1–9-year-olds.

For all EUs, the sample for estimation of TT prevalence was composed of adults living in the households selected to survey children. Because TT was expected to be rarer than TF, the TT prevalence estimate will have less relative precision than the TF estimate.

Training

Using trainers certified to train graders and recorders by Tropical Data, training and certification of survey graders and recorders was performed, followed by combined training of field teams on survey procedures. We used the training system in the second and third versions of the Tropical Data Training manual (please see below for details of version differences).19,20

Data collection

All data were captured electronically using a purpose-built Open Data Kit-based Android Smartphone application. During each day of fieldwork, survey teams moved house-to-house collecting data. Once household heads had agreed that their house could be enrolled, the Global Positioning System (GPS) coordinates of the household were recorded and the recorders administered the WASH questionnaire. WASH questions were derived from the United Nations Children’s Fund (UNICEF)/WHO Joint Monitoring Programme (JMP), modified for trachoma surveys.21 In this survey series, due to an update in the data collection form that occurred part-way through the series, two versions of the WASH questionnaire were employed for hand washing facility observation. Version two was used in Gechi, Mulo & Bereh, Sebeta Hawas, Sululta, Welmera, Aleltu, Kimbibit and A/G/Beret. In it, data recorders observed handwash stations within 15 m of the latrine; where there was no latrine, no handwash station observations were carried out. Version three was used in Botor Tolay, Omo Beyam and Omo Nada; data recorders observed handwash stations on the household premises or in the yard outside the premises, regardless of the presence or absence of a latrine. Water source type, water source proximity, latrine ownership and latrine status were the same between the two versions: only the handwash station question differed. Each individual consented for inclusion was examined using binocular 2.5× magnifying loupes, and sunlight or a torch for illumination. Certified graders determined the presence or absence of trichiasis, TF and TI according to the then-current WHO simplified grading system. As a result of recommendations made at the 4th Global Scientific Meeting on Trachoma (GSM4) in November 2018, the definition of TT in the WHO simplified system was refined part way through this survey series (at the same time as the change from version 2 to version 3 of the WASH questionnaire). TT was therefore graded slightly differently in the surveys conducted using the pre-GSM4 methodology (Gechi, Mulo & Bereh, Sebeta Hawas, Sululta, Welmera, Aleltu, Kimbibit and A/G/Beret) compared to the surveys conducted using the post-GSM4 methodology (Botor Tolay, Omo Beyam and Omo Nada). In the former, TT was defined as at least one eyelash touching the eyeball or evidence of recent epilation of in-turned eyelashes,22 and the eyelid from which the aberrant eyelash(es) emanated was not recorded. In the latter, TT was defined as at least one eyelash from the upper eyelid touching the eyeball, or evidence of recent epilation of in-turned eyelashes from the upper eyelid.23 In all 11 EUs, regardless of whether pre- or post-GSM4, TT grading protocols were used. Where trichiasis was recorded as being present in an eye, the individual was asked whether they had been offered management for it, and whether they had accepted it.24 Those who had not been offered surgery or could not remember having been offered it, for at least one eye with TT were considered to have TT “unknown to the health system”.25 Where one or more resident 1–9-year-old was missing at the time of the first visit, the household was re-visited once before the end of the day.

Quality issues

One survey coordinator assigned by the Regional Health Bureau had responsibility for linking survey teams with local authorities, communicating with the regional team in case of any issues in the field, overseeing the survey team, checking availability of necessary resources and logistics on a daily basis, and checking the security status of the targeted EUs before field deployment. In addition, two-layer supervision was used to maintain survey quality. The first layer involved supervisors who were non-ophthalmologist eye health professionals qualified as supervisors and grader trainers (scoring kappas ≥0.8 in field inter-grader agreement tests against Tropical Data reference graders). These first-line supervisors were generally responsible for seven survey teams and traveled with them each day to provide technical support. They oversaw whether the team was properly following the survey protocol or deviating from it, checked how well the team was recording necessary data and occasionally undertook examinations where graders were not able to do so. The second layer was composed of lead supervisors/trainers who were ophthalmologists, providing technical backup to both first-line supervisors and data collectors whenever required. The senior supervisors provided weekly plan to each team, made sure that data were collected from all targeted clusters as per the plan, technically assisted survey team in case they encountered complicated eye health problems that were beyond the capacity of graders/first line supervisors, verified lower eyelid trichiasis cases or TT cases in those aged <15 years whenever they were reported, and reported to regional and national team leads. Quality control and quality assurance measures used throughout the survey process are described in more detail elsewhere.26,27

Data analysis

Data were stored on the smartphone’s micro-secure digital (SD) card, until a data-enabled mobile network or WiFi signal was available then transmitted to a central database for cleaning and analysis. Analysis of TF and TT prevalence, including adjustments for age and gender and estimation of confidence intervals (CIs), was conducted as described elsewhere.21,28 WASH facilities were categorized in line with UNICEF/WHO JMP recommendations.

Results

Fieldwork took place between January 2017 and March 2020. Across 11 EUs, a total of 31,991 individuals were enumerated, 29,230 consenting individuals were examined and 2,528 individuals were absent on the day of the household visit. Fifty-four percent of examined individuals were female. Details from each EU are shown in Table 1.

Table 1.

Population enumerated and participants examined in 11 trachoma surveillance survey evaluation units (EUs) of Oromia Region, Ethiopia, January 2017–March 2020.

z Total Enumerated Total Female Enumerated Total Examined Total Female Examined Total Absent Total Refused
Gechi 3075 1536 2870 1480 193 12
Mulo & Bereh 2916 1451 2480 1340 386 50
Sebata Awas 2920 1432 2513 1347 349 58
Sululta 2991 1517 2538 1408 410 43
Welmera 2942 1488 2578 1413 331 33
Aleltu 3103 1510 2857 1464 230 16
Kimbibit 3062 1491 2777 1438 268 17
Abuna Gindeberet 2988 1561 2817 1504 169 2
Boter Tolay 2537 1357 2472 1345 64 1
Omo Beyam 2751 1499 2690 1475 61 0
Ommo Nadda 2706 1507 2638 1493 67 1
Total 31991 16349 29230 15707 2528 233

Eight of 11 EUs had an age-adjusted TF prevalence estimate in 1–9-year-olds ≥5%, above the trachoma elimination threshold.29 There was considerable variation in TF prevalence between EUs: the lowest (2.7%, 95%CI 2.1–5.4) was reported in Aleltu district, while the highest (13.8%, 95%CI 8.9–20.4) was reported in Sebata Hawas district (Table 2).

Table 2.

Prevalence of trachomatous inflammation—follicular (TF) in 11 trachoma surveillance survey evaluation units (EUs) of Oromia Region, Ethiopia, January 2017–March 2020.

EU 1–9-year-olds examined 1–9-year-olds with TF Age-adjusted prevalence of TF in
1–9- year-olds (%)
95% confidence interval around TF prevalence estimate
Gechi 1251 47 3.8 [1.9–6.5]
Mulo & Bereh 876 60 6.7 [3.3–7.8]
Sebeta Hawas 893 123 13.8 [8.9–20.4]
Sululta 976 65 6.6 [3.9–9.7]
Welmera 904 78 8.6 [3.5–10.6]
Aleltu 1060 29 2.7 [2.1–5.5]
Kimbibit 1133 50 4.4 [3.3–7.4]
Abuna Ginda Beret 1089 98 9.0 [6.0–13.3]
Botor Tolay 976 64 6.6 [3.6–9.5]
Omo Beyam 1236 89 7.0 [4.5–12.5]
Omo Nada 1123 120 10.7 [6.5–13.1]
Total 11,517 823    

TF prevalence estimates were lower than at baseline for all surveyed EUs (Figure 1). For example, the TF prevalence in Abuna Gindeberet was 55% at baseline (in 2011); at impact survey (in 2017), following five rounds of MDA, it was 3%, and at the time of surveillance survey (in 2018), it was 9.0%. The TF prevalence was <5% at the time of these surveillance surveys only in Gechi, Kimbibit and Aleltu.

Figure 1.

Figure 1.

Trachomatous inflammation—follicular (TF) prevalence in 1–9-year-olds over time, 11 evaluation units, Oromia Region, Ethiopia. (Methodologies and results of baseline and impact surveys are published elsewhere.)30,31

Of 17,713 individuals aged ≥15 years examined, 179 had TT. In 7 of the 11 EUs the age- and gender-adjusted TT prevalence unknown to the health system among ≥15-year-olds was ≥0.2%. Four EUs (Mulo & Bereh, Sululta, Welmera and Kimbibit had a TT prevalence <0.2%, Table 3).

Table 3.

Prevalence of trachomatous trichiasis (TT) in ≥15-year-olds (%), 11 trachoma surveillance survey evaluation units (EUs), Oromia Region, Ethiopia, January 2017–March 2020.

EU ≥15-year-olds examined Data from pre-GSM4 surveys (both upper and lower eyelid trichiasis included as “TT”)
Data from post-GSM4 surveys (only upper eyelid trichiasis included as “TT”)
≥15-year-olds with TT ≥15-year-olds with TT unknown to the health system Age- and gender-adjusted prevalence of TT unknown to the health system in ≥15-year- olds (%) 95% confidence interval around age- and gender-adjusted prevalence of TT unknown to the health system in ≥15- year-olds (%) ≥15-year-olds with upper eyelid TT ≥15-year-olds with upper eyelid TT unknown to the health system Age- and gender-adjusted prevalence of upper eyelid TT unknown to the health system in ≥15-year-olds (%) 95% confidence interval around age- and gender-adjusted prevalence of upper eyelid TT unknown to the health system in ≥15- year-olds (%)
Gechi 1619 11 8 0.32 0.2–0.9 NA NA NA NA
Mulo& Bereh 1604 6 4 0.12 0.0–0.4 NA NA NA NA
Sebeta Hawas 1620 21 13 0.49 0.4–1.1 NA NA NA NA
Sululta 1562 8 6 0.19 0.0–0.5 NA NA NA NA
Welmera 1674 8 4 0.09 0.0–0.7 NA NA NA NA
Aleltu 1797 12 11 0.62 0.2–1.4 NA NA NA NA
Kimbibit 1644 5 3 0.11 0.0–0.3 NA NA NA NA
A/G/Beret 1728 29 18 0.99 0.5–2.2 NA NA NA NA
Botor Tolay 1496 NA NA NA NA 13 11 0.61 0.2–1.4
Omo Beyam 1454 NA NA NA NA 17 16 0.64 0.3–1.1
Omo Nada 1515 NA NA NA NA 49 39 1.27 1–1.9
Total 17,713 100 67     79 66    

Overall, about a quarter (23%) of 8,804 visited households from the 11 EUs reported access to an improved source of water for drinking within a 30-minute return journey. The proportion of households which reported access to an improved source of water for drinking within a 30-minute journey ranged between 20% in Botor Tolay district and 39% in Mulo and Bereh districts. Only 5% of all visited households had access to an improved latrine. Household access to improved latrines ranged from 0% in Aleltu to 21% in Abuna Ginde Beret. In all EUs, the proportion of households with a hand washing station with water and soap was <5% (Table 4).

Table 4.

Household-level access to water, sanitation and hygiene facilities, trachoma surveillance surveys, Oromia Region, Ethiopia, January 2017–March 2020.

Evaluation unit Number of clusters Number of house holds Households with an improved drinking water source within 30- minute journey (number [%]) Households with an improved latrine (number [%]) Households with a hand wash station with water & soap within 15 m of latrine (number [%]) Households with a hand wash station with soap and water on the household premises (number [%])
Gechi 26 789 276 [35] 1 [0.1] 1 [0.1] NA
Mulo& Bereh 28 836 166 [20] 8 [1.0] 3 [0.4] NA
Sebta Haws 28 840 194 [23] 15 [1.8] 12 [1.4] NA
Sululta 26 798 224 [28] 59 [7.4] 14 [1.8] NA
Welmera 28 846 308 [36] 5 [0.6] 15 [1.8] NA
Aleltu 26 789 221 [28] 0 [0.0] 1 [0.1] NA
Kimbibit 26 791 286 [36] 11[1.4] 3 [0.4] NA
A/G/Beret 26 779 196 [25] 163 [20.9] 38 [4.9] NA
Botor Tolay 26 779 304 [39] 83 [10.7] NA 26 [3.3]
Omo Beya 26 780 225 [29] 39 [5.0] NA 1 [0.1]
Omo Nada 26 777 238 [31] 48 [6.2] NA 1 [0.1]
Total   8,804 2,638 [23] 432 [4.9] 87 28

Discussion

According to WHO recommendations, EUs with a TF prevalence in 1−9-year-olds <5% at impact survey should receive no further MDA for 2 years and then be re-surveyed to determine whether the low TF prevalence has been sustained.14 At impact survey, all 11 EUs described in this manuscript had TF prevalence <5%.30 However, by the time of the surveillance surveys reported here, two years after MDA was stopped, only three EUs (Aleltu, Kimbibit and Gechi) had maintained TF <5%. The prevalence of TF was in the 5.0−9.9% range in six EUs, and >10-29.9% in two EUs. One or three renewed rounds of MDA respectively are now warranted in these EUs to further reduce the prevalence of C. trachomatis infection.32

Our surveys cannot provide explanations as to why TF recrudesced in these EUs, but we can speculate. It is notable, for example, that despite ongoing work, the overall coverage of WASH access in these EUs was low. More than three-quarters of households surveyed had to undertake a round trip of >30 minutes to reach an improved drinking water source. Living in water-scarce environments such as these may discourage face washing.33,34 Similarly, more than 95% of households did not access an improved latrine, suggesting an abundance of breeding sites for eye-seeking flies in these communities.35 A reduction in improved latrine coverage was observed in four of the seven EUs for which data were available for both the baseline and surveillance surveys. These metrics are suggestive of an environment at high risk of ocular C. trachomatis transmission, and are associated with high TF prevalence.

The adjusted prevalence of TT unknown to the health system in ≥15-year-olds remained above the elimination target in seven of the 11 surveyed EUs. Only four had achieved a prevalence of <0.2%. This is disappointing given the efforts that have been made to provide TT surgical services in the region. Surgical services should be further strengthened and active case finding undertaken throughout the region to identify and manage cases of TT. TT prevalence estimates should also be interpreted with caution as the sample size was powered to provide precision around the TF prevalence estimate. According to WHO recommendations, either 2818 adults aged ≥ 15 years should be examined, or 30 clusters per EU surveyed36: neither of these conditions were met in any of these surveys

We acknowledge additional limitations to our work. First, because of differences in sampling frame and methodology, comparisons with data before this study should be made with extreme caution. In the baseline surveys covering the EUs described here, multiple districts were surveyed as a single EU.25 In impact and surveillance surveys, those EUs were re-framed with smaller population sizes (single districts for most EUs; two districts for one EU). Where multiple districts were surveyed as a single EU at baseline, baseline prevalences of the parent EU were assigned to each of the individual offspring EUs for the purposes of Figure 1, though this is not really epidemiologically valid. Pre-MDA estimates generated using the Ethiopia National Trachoma Programme protocol31 had even greater methodological differences to these surveillance surveys than did the pre-MDA estimates generated with support from the GTMP. It is therefore difficult to contextualize the findings from this study using baseline and impact survey data. Second, we collected data on WASH infrastructure, but not on objective WASH facility usage or other behaviors37,38 which might be relevant to transmission of infection. It is likely that important drivers of transmission went unmeasured here and we continue to be unaware of their potential impact on prevalence. Though the evidence base for the F and E components of SAFE is weak,39,40 modeling suggests that small differences in transmission intensity could make critical differences to trachoma elimination prospects over the longer term.41

The progress of Oromia, the largest region of Ethiopia, towards elimination of trachoma as a public health problem is of paramount importance to the global trachoma elimination programme. It is disappointing that these surveillance surveys indicate that TF prevalence targets were not maintained two years after MDA cessation. With these data, however, we can plan for further interventions and operational research to improve future strategies; that work has already begun.42–46 It is also clear that improvements in WASH are needed, not just for trachoma elimination purposes or for the broader neglected tropical disease agenda, but to achieve general improvement in the quality of life of people living in this region.47

Funding Statement

Survey fieldwork was supported by RTI International and Fred Hollows Foundation. Core support to Tropical Data has been provided by the United Kingdom’s Foreign, Commonwealth and Development Office, the ENVISION project, Fred Hollows Foundation, the International Trachoma Initiative, the Queen Elizabeth Diamond Jubilee Trust, RTI International, Sightsavers, USAID and the World Health Organization (WHO). AWS is a staff member of WHO.

Disclosure statement

RW, AB and SB were employees of the International Trachoma Initiative, which receives an operating budget andresearch funds from Pfizer Inc., the manufacturer of Zithromax (azithromycin). EMHE receives salary support from the International Trachoma Initiative. No potential conflict of interest was reported by the other authors

Disclaimer

The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.

References

  • 1.Solomon AW, Holland MJ, Burton MJ, et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet. 2003;362(9379):198–204. doi: 10.1016/S0140-6736(03)13909-8. [DOI] [PubMed] [Google Scholar]
  • 2.Last AR, Burr SE, Weiss HA, et al. Risk factors for active trachoma and ocular Chlamydia trachomatis infection in treatment-naive trachoma-hyperendemic communities of the Bijagos Archipelago, Guinea Bissau. PLoS Negl Trop Dis. 2014;8(6):e2900. doi: 10.1371/journal.pntd.0002900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Last A, Versteeg B, Shafi O, et al. Detecting extra-ocular Chlamydia trachomatis in a trachoma-endemic community in Ethiopia: identifying potential routes of transmission. Plos Negl Trop Dis. 2020;14(3):e0008120. doi: 10.1371/journal.pntd.0008120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Miller K, Pakpour N, Yi E, et al. Pesky trachoma suspect finally caught. Br J Ophth. 2004;88(6):750–751. doi: 10.1136/bjo.2003.038661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Solomon AW, Burton MJ, Gower, EW, Harding-Esch EM, Oldenburg CE, Traoré, L, Taylor HR.. Trachoma. Nat Rev Dis Primers. 2022;8(1):32. doi: 10.1038/s41572-022-00359-5. [DOI] [PubMed] [Google Scholar]
  • 6.Francis V, Turner, V. Achieving community support for trachoma control (WHO/PBL/93.36). Geneva: World Heal Organization. 1993. [Google Scholar]
  • 7.World Health Organization . WHO Alliance for the Global Elimination of Trachoma by 2020: progress report, 2019. Wkly Epidemiol Rec. 2020;95(30):349–360. [Google Scholar]
  • 8.International Trachoma Initiative . Global Atlas of Trachoma [http://www.trachomaatlas.org]. 2020. Decatur: Task Force for Global Health. [Google Scholar]
  • 9.Bero B, Macleod C, Alemayehu W, et al. Prevalence of and risk factors for trachoma in Oromia regional state of Ethiopia : results of 79 population-based prevalence surveys conducted with the Global Trachoma Mapping Project. Ophthalmic Epidemiol. 2016;23(6):392–405. doi: 10.1080/09286586.2016.1243717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Deribe K, Kgt M, Gebre T, et al. The burden of neglected tropical diseases in Ethiopia, and opportunities for integrated control and elimination. Parasit Vectors. 2012;5(1):240. doi: 10.1186/1756-3305-5-240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Federal Democratic Republic of Ethiopia Population Census Commision . Central Statistical Agency of Ethiopia. Population and Housing Census Report 2007. Addis Ababa. Published online 2008. [Google Scholar]
  • 12.Oromia Regional State Health Bureau Addis Ababa . Regional Annual Health Sector Plan of 2013 E C (2020/21 GC). 2020.
  • 13.Emerson PM, Hooper PJSV, Sarah V. Progress and projections in the program to eliminate trachoma. PLoS Negl Trop Dis. 2017;11(4):e0005402. doi: 10.1371/journal.pntd.0005402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.World Health Organization Strategic and Technical Advisory Group on Neglected Tropical Diseases . Technical consultation on trachoma surveillance September 11−12, 2014, Task Force for Global Health, Decatur, USA (WHO/HTM/NTD/2015.02). Geneva: World Health Organization; 2015. [Google Scholar]
  • 15.World Health Organization . Report of the 3rd global scientific meeting on trachoma. Johns Hopkins University, Baltimore, MA, 19-20 July 2010. (WHO/PBD/2.10). [Google Scholar]
  • 16.World Health Organization Strategic and Technical Advisory Group on Neglected Tropical Diseases. . Design parameters for population-based trachoma prevalence surveys (WHO/HTM/NTD/PCT/2018.07). Geneva: World Health Organization. 2018. [Google Scholar]
  • 17.Central Statistical Agency . Ethiopia Mini Demographic and Health Survey 2019. Addis Ababa: Government of Ethiopia. 2019. [Google Scholar]
  • 18.Macleod CK, Bailey RL, Dejene M, et al. Estimating the intracluster correlation coefficient in population-based trachoma prevalence surveys: results from a meta-regression of 261 standardised pre-intervention surveys in Ethiopia, Mozambique and Nigeria. Am J Epidemiol. 2020;189(1):68–76. doi: 10.1093/aje/kwz196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Courtright P, MacArthur C, Macleod C. et al. Tropical Data: Training System for Trachoma Prevalence Surveys (version 2). London: International Coalition for Trachoma Control. 2017. [Google Scholar]
  • 20.Courtright P, MacArthur, C, Macleod CK. et al. Tropical Data: training system for trachoma prevalence surveys (version 3). London: International Coalition for Trachoma Control. 2019. [Google Scholar]
  • 21.Solomon AW, Pavluck AL, Courtright P, et al. The global trachoma mapping project: methodology of a 34-country population-based study. Ophthalmic Epidemiol. 2015;22(3):214–225. doi: 10.3109/09286586.2015.1037401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Thylefors B, Dawson CR, Jones BR, West SKTH. A simple system for the assessment of trachoma and its complications. Bull World Heal Organ. 1987;65:477–483. [PMC free article] [PubMed] [Google Scholar]
  • 23.Solomon AW, Kello AB, Bangert M, et al. The simplified trachoma grading system, amended. Bull World Heal Organ. 2020;98(10):698–705. doi: 10.2471/blt.19.248708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hiep NX, Ngondi JM, Anh VT, et al. Trachoma in Viet Nam: results of 11 surveillance surveys conducted with the Global Trachoma Mapping Project. Ophthalmic Epidemiol. 2018;25(sup1):93–102. doi: 10.1080/09286586.2018.1477964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.World Health Organization . Report of the 3rd global scientific meeting on trachoma, Johns Hopkins University, Baltimore, MA, 19-20 July 2010 (WHO/PBD/2.10). Geneva: World Health Organization; 2010. [Google Scholar]
  • 26.Solomon AW, Willis R, et al. Quality assurance and quality control in the global trachoma mapping project. Am J Trop Med Hyg. 2018;99(4):858–863. doi: 10.4269/ajtmh.18-0082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Solomon AW, Le Mesurier RT, Williams WJ. A diagnostic instrument to help field graders evaluate active trachoma. Ophthalmic Epidemiol 2018;25(5–6) . :399–402. doi: 10.1080/09286586.2018.1500616 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Elshafie BE, Osman KH, Macleod C, et al. The epidemiology of trachoma in Darfur states and Khartoum state, Sudan: results of 32 population-based prevalence surveys. Ophthalmic Epidemiol. 2016;23(6):381–391. doi: 10.1080/09286586.2016.1243718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.World Health Organization . Validation of Elimination of Trachoma as a Public Health Problem (WHO/HTM/NTD/2016.8). Geneva: World Heal Organization; 2016. [Google Scholar]
  • 30.Miecha H, Dejene M, Adugna D. et al. Prevalence of Trachoma after Implementation of Trachoma Elimination Interventions in Oromia Regional State: results of impact surveys in 131 evaluation units covering 139 districts Ophthalmic Epidemiol. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Oromia Regional Health Bureau . Prevalence of Trachoma in Five Zones of Oromia Region, Ethiopia. Addis Ababa: Sub-Saharan African Med Res Found; Published online 2010 [Google Scholar]
  • 32.Evans JR, Solomon AW, Kumar R, et al. Antibiotics for trachoma. Cochrane Database Syst Rev. 2019;9:CD0001860 doi: 10.1002/14651858.CD001860.pub4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Cairncross S, Cuff JL. Water use and health in Mueda, Mozambique. Trans R Soc Trop Med Hyg. 1987;81(1):51–54. doi: 10.1016/0035-9203(87)90280-X. [DOI] [PubMed] [Google Scholar]
  • 34.Bailey R, Downes B, Downes R, Mabey D. Trachoma and water use; a case control study in a Gambian village. Trans R Soc Trop Med Hyg. 1991;85(6):824–828. doi: 10.1016/0035-9203(91)90470-J. [DOI] [PubMed] [Google Scholar]
  • 35.Emerson PM, Bailey RL, Walraven GEL, Lindsay SW. Human and other faeces as breeding media of the trachoma vector Musca sorbens. Med Vet Entomol. 2001;15(3):314–320. doi: 10.1046/j.0269-283x.2001.00318.x. [DOI] [PubMed] [Google Scholar]
  • 36.World Health Organization . Design and validation of a trachomatous trichiasis-only survey (WHO/HTM/NTD/PCT/2017.08). Geneva: World Health Organization. 2018. [Google Scholar]
  • 37.West S, Munoz B, Lynch M, et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet. 1995;345(894):155–158. doi: 10.1016/S0140-6736(95)90167-1. [DOI] [PubMed] [Google Scholar]
  • 38.Delea MG, Solomon H, Solomon AW, Freeman MC. Interventions to maximize facial cleanliness and achieve environmental improvement for trachoma elimination: a review of the grey literature. PLoS Negl Trop Dis. 2018;12(1):e0006178. doi: 10.1371/journal.pntd.0006178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Rabiu M, Alhassan MB, Ejere HO, Evans JR. Environmental sanitary interventions for preventing active trachoma. Cochrane Database Syst Rev. 2012. 2;CD004003. doi: 10.1002/14651858.CD004003.pub4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Ejere HO, Alhassan MB, Rabiu M. Alhassan MB RMF washing promotion for preventing active trachoma. Face washing promotion for preventing active trachoma. Cochrane Database Syst Rev. 2015. 2;CD003659. doi: 10.1002/14651858.CD003659.pub4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Pinsent A, Burton MJ, Gambhir M. Enhanced antibiotic distribution strategies and the potential impact of facial cleanliness and environmental improvements for the sustained control of trachoma: a modelling study. BMC Med. 2016;14(1):1–10. doi: 10.1186/s12916-016-0614-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Robinson A, Bickford-Smith J, Abdurahman Shafi O, et al. Towards an odour-baited trap to control Musca sorbens, the putative vector of trachoma. Sci Rep. 2021;11(1):14209. doi: 10.1038/s41598-021-91609-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Versteeg B, Vasileva H, Houghton J, et al. Viability PCR shows that non-ocular surfaces could contribute to transmission of Chlamydia trachomatis infection in trachoma. PLoS Negl Trop Dis. 2020;14(7):e0008449. doi: 10.1371/journal.pntd.0008449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Last A, Versteeg B, Shafi Abdurahman O, et al. Detecting extra-ocular Chlamydia trachomatis in a trachoma-endemic community in Ethiopia: identifying potential routes of transmission. PLoS Negl Trop Dis. 2020;14(3):e0008120. doi: 10.1371/journal.pntd.0008120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Robinson A, Bristow J, Holl MV, et al. Responses of the putative trachoma vector, Musca sorbens, to volatile semiochemicals from human faeces. Frech(Switzerland) PLoS Negl Trop Dis. 2020;14(3):e0007719. doi: 10.1371/journal.pntd.0007719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Czerniewska A, Versteeg A, Shafi O, et al. Comparison of face washing and face wiping methods for trachoma control: a pilot study. Am J Trop Med Hyg. 2020;102(4):740–743. doi: 10.4269/ajtmh.19-0726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Boisson S, Wohlgemuth L, Yajima A, et al. Building on a decade of progress in water, sanitation and hygiene to control, eliminate and eradicate neglected tropical diseases. Trans R Soc Trop Med Hyg. 2021;115(2):185–187. doi: 10.1093/trstmh/trab001. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Ophthalmic Epidemiology are provided here courtesy of Taylor & Francis

RESOURCES